Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date β€” because we believe great analysis should be held accountable.

AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
Madrigal Pharmaceuticals (MDGL) is poised for a major short squeeze. With 24% of shares short, bears are misreading the data. The company has neutralized the GLP-1 threat via a licensing deal, extended key patents to 2045, and is hitting revenue milestones.

The 24% Short Trap: Why Madrigal Pharmaceuticals (MDGL) is Orchestrating the Biotech Squeeze of the Decade

2026-03-27BullishStrongChange from report: -6.6%1M: +1.8%3M: +3.3%

Madrigal Pharmaceuticals (MDGL) is poised for a major short squeeze. With 24% of shares short, bears are misreading the data. The company has neutralized the GLP-1 threat via a licensing deal, extended key patents to 2045, and is hitting revenue milestones.